GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Owner Earnings per Share (TTM)

Rosetta Genomics (FRA:RQ1) Owner Earnings per Share (TTM) : 0.00 (As of Dec. 2016)


View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Rosetta Genomics's Owner Earnings per Share (TTM) ended in Dec. 2016 was €0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Rosetta Genomics's Owner Earnings per Share (TTM) or its related term are showing as below:



FRA:RQ1's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.165
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Rosetta Genomics's Earnings per Share (Diluted) for the three months ended in Jun. 2017 was €-0.72. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was €-5.32. It's PE Ratio ratio for today is At Loss.

Rosetta Genomics's EPS without NRI for the three months ended in Jun. 2017 was €-0.40. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2017 was €-5.00. It's PE Ratio without NRI ratio for today is At Loss.


Rosetta Genomics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Rosetta Genomics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Owner Earnings per Share (TTM) Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -10.82 3.89 0.03

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 -0.86 -0.89 0.03 2.23

Competitive Comparison of Rosetta Genomics's Owner Earnings per Share (TTM)

For the Diagnostics & Research subindustry, Rosetta Genomics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Price-to-Owner-Earnings falls into.



Rosetta Genomics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Rosetta Genomics's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -15.39
Depreciation, Depletion and Amortization 0.86
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.16
Change In Working Capital 3.36
Shares Outstanding (Diluted Average) 1.74

1. Start with "Net Income" from income statement. Rosetta Genomics's Net Income for the trailing twelve months (TTM) ended in Dec. 2016 was €-15.39 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Rosetta Genomics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2016 was €0.86 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Rosetta Genomics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2016 was €0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = €0.16 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Rosetta Genomics's 5-Year Average Maintenance Capital Expenditure = €0.16 Mil

5. "Change In Working Capital" is from cashflow statement. Rosetta Genomics's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2016 was €3.36 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Rosetta Genomics's Shares Outstanding (Diluted Average) for the months ended in Dec. 2016 was 1.743 Mil.

Rosetta Genomics's Onwer Earnings Per Share for Dec. 2016 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -15.389 +0.857+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.1626+3.361)/1.743
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.01/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Rosetta Genomics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (FRA:RQ1) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines